Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Corporation Limited announced that the Department of Health, the Government of the HKSAR has approved a NDA for XPOVIO®.